stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) EBITDA
argenex SE's EBITDA for fiscal 2025 was $1.1B, compared with −$4.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.7B. Over the past ten years it has ranged from −$616.0M (fiscal 2022) to $1.1B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. argenex SE ranks 3rd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.1B | — |
| FY2024 | −$4.1M | — |
| FY2023 | −$313.7M | — |
| FY2022 | −$616.0M | — |
| FY2021 | −$342.9M | — |
| FY2020 | −$473.7M | — |
| FY2019 | −$197.6M | — |
| FY2018 | −$96.1M | — |
| FY2017 | −$25.4M | — |
| FY2016 | −$23.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $485.0M | (1.82%) |
| Jun 2026 | $494.0M | 25.38% |
| Mar 2026 | $394.0M | 7.41% |
| Dec 2025 | $366.8M | 5.71% |
| 25 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $5.4B |
| ARGX argenex SE | $1.7B |
| RPRX Royalty Pharma PLC compare | $1.5B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.4B |
| GMAB Genmab A/S Sponsored ADR compare | $1.2B |
| INCY Incyte Corporation compare | $724.9M |
| ROIV Roivant Sciences Ltd. compare | −$593.3M |
| RVMD Revolution Medicines, Inc. compare | −$1.6B |
| MRNA Moderna, Inc. compare | −$3.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement